Japanese anti-clotting drug Savaysa gets FDA approval

January 10, 2015 6:00 AM

3 0

The US Food and Drug Administration (FDA) has given green signal to drug Savaysa (edoxaban) to lower the risk of stroke and systemic embolism as well as prevent the condition of pulmonary embolism and deep vein thrombosis.

The health regulatory body gave its nod to the drug to treat the patients with atrial fibrillation (not triggered by a heart valve problem) and pulmonary embolism or deep vein thrombosis.

Read more

To category page